Sihuan to develop favipiravir as COVID-19 treatment

2 March 2020

A clinical trial of oral favipiravir, developed by Hong Kong-based Sihuan Pharmaceutical (HKEX: 0460), is to investigate the drug’s potential against coronavirus (COVID-19).

Led by Beijing Chaoyang Hospital, the trial is part of a program by Sihuan and the Institute of Microbiology Epidemiology, a division of the Chinese armed forces.

The parallel dose exploration study will enroll 60 cases of regular COVID-19, for a treatment period of 10 days. The firm says it will initiate efficacy and safety verification trials of larger scale once results are obtained.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK